Blood 2018 Mar 8

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.

Related Questions

What therapy would you consider for refractory pediatric HR AML with KMT2Ar to try to induce remission for transplant?

Pediatric Hematology/Oncology · Baylor College of Medicine

For any case of refractory AML regardless of the cytogenetics, we turn to regimens used in the relapse setting. Nowadays common choices are based on fludarabine/cytarabine (FLA), CPX-351, and/or venetoclax. For this patient, I would focus on FLA and venetoclax-based regimens. To take advantage of th...